Bozko P - Search Results

1

Editorial: Helicobacter pylori eradication therapy: advantages and disadvantages.

Bien J, Bozko M, Malek NP, Bozko P. Bien J, et al. Among authors: bozko p, bozko m. Curr Pharm Des. 2014;20(28):4487-8. doi: 10.2174/138161282028140704103024. Curr Pharm Des. 2014. PMID: 24998645 No abstract available.

2

Editorial: Gut Microbiota and Gastrointestinal Diseases: to Treat or Not To Treat.

Bien J, Bozko M, P Malek N, Bozko P. Bien J, et al. Among authors: bozko p, bozko m, p malek n. Curr Pharm Des. 2013 Oct 14. Online ahead of print. Curr Pharm Des. 2013. PMID: 24180401 No abstract available.

3

Editorial: Gut microbiota and gastrointestinal diseases: to treat or not to treat.

Bien J, Bozko M, Malek NP, Bozko P. Bien J, et al. Among authors: bozko p, bozko m. Curr Pharm Des. 2014;20(28):4533-4. Curr Pharm Des. 2014. PMID: 24998646 No abstract available.

4

Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?

Podhorecka M, Macheta A, Bozko M, Bozko A, Malek NP, Bozko P. Podhorecka M, et al. Among authors: bozko a, bozko p, bozko m. Curr Cancer Drug Targets. 2016;16(8):652-658. doi: 10.2174/1568009616666160427103930. Curr Cancer Drug Targets. 2016. PMID: 27117115 Review.

5

Editorial (Thematic Issue: Pathogenetic Mechanisms of CLL - A Target in Therapy).

Bozko M, Podhorecka M, Macheta A, Bozko A, Malek NP, Bozko P. Bozko M, et al. Among authors: bozko a, bozko p. Curr Cancer Drug Targets. 2016;16(8):651. doi: 10.2174/156800961608160902101746. Curr Cancer Drug Targets. 2016. PMID: 27758697 No abstract available.

6

Editorial: DNA Damage as a Strategy for Anticancer Chemotherapy.

Bozko M, Bozko A, Scholta T, Malek NP, Bozko P. Bozko M, et al. Among authors: bozko a, bozko p. Curr Med Chem. 2017;24(15):1487. doi: 10.2174/092986732415170630115722. Curr Med Chem. 2017. PMID: 28728539

7

Dysregulation of Carnosine Metabolism in Progression of Diseases.

Bozko M, Drozak J, Malek NP, Bozko P. Bozko M, et al. Among authors: bozko p. Curr Med Chem. 2020;27(11):1713. doi: 10.2174/092986732711200423112140. Curr Med Chem. 2020. PMID: 32340600 No abstract available.

8

Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer.

Klein SM, Bozko M, Toennießen A, Malek NP, Bozko P. Klein SM, et al. Among authors: bozko p. Curr Med Chem. 2022;29(24):4293-4300. doi: 10.2174/0929867329666220112141211. Curr Med Chem. 2022. PMID: 35023452

9

Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.

El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. El Khatib M, et al. Among authors: bozko p. PLoS One. 2013 Oct 30;8(10):e77433. doi: 10.1371/journal.pone.0077433. eCollection 2013. PLoS One. 2013. PMID: 24204826 Free PMC article.

10

Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma.

Bhuria V, Xing J, Scholta T, Bui KC, Nguyen MLT, Malek NP, Bozko P, Plentz RR. Bhuria V, et al. Among authors: bozko p. Exp Cell Res. 2019 Dec 15;385(2):111671. doi: 10.1016/j.yexcr.2019.111671. Epub 2019 Oct 18. Exp Cell Res. 2019. PMID: 31634481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters